ArticleThe Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics2022
Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic.
Article in The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Long-Acting Cabotegravir Injections Are More Acceptable Than Long-Acting Lenacapavir Injections After One Dose: Results From the CLARITY Randomized Crossover Study.Advances in therapy · 2026Trial
- Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.Antimicrobial agents and chemotherapy · 2024Trial
- Review
- Brief Report: To Err Is Human, to Persist Is Diabolical: Are We Repeating the Same Cost and Insurance Coverage Mistakes Again With Injectable PrEP?Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Cost-effectiveness of leveraging long-acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities.Journal of the International AIDS Society · 2026Article
- Knowledge, attitutes and perceptions of medical and pharmacy students about HIV pre-exposure prophylaxis: a cross-sectional survey from Pakistan.BMC medical education · 2025Article
- Exploration of implementation determinants and strategies for same-day oral PrEP in community-based organizations and federally qualified health centers.Implementation science communications · 2025Article
- Trends in HIV Preexposure Prophylaxis Use Before and After Launch of the Ending the HIV Epidemic in the US Initiative, 2016-2023.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- PrEP Navigator Perceptions of the Implementation of Injectable PrEP on HIV Prevention in Tennessee.International journal of environmental research and public health · 2025Article
- A modeling study of pre-exposure prophylaxis to eliminate HIV in Taiwan by 2030.Communications medicine · 2025Article
- Supporting Access to HIV Pre-Exposure Prophylaxis in a Shifting Financial and Insurance Landscape.AJPM focus · 2025Article
- Strengthening PrEP services at community-based organizations for Latinx men who have sex with men: an implementation science approach.Archives of public health = Archives belges de sante publique · 2025Article
- Multi-level correlates of oral pre-exposure prophylaxis discontinuation among English and Spanish-speaking transgender women of color in New York City: The TURNNT cohort study.International journal of transgender health · 2025Article
- A latent class analyses of economic stability, medical mistrust, and barriers to care in relation to PrEP awareness in Black communities in Miami, FL.PLOS global public health · 2025Article
- PrEP for people who use opioids: A NIDA clinical trials network survey study in Southern U.S. cities where HIV incidence is high.Drug and alcohol dependence · 2024Article
- Willingness to pay and price elasticity of demand for long-acting injectable cabotegravir among men who have sex with men in Guangxi, China.Frontiers in pharmacology · 2024Article
- Protocol for a systematic search and critical discourse analysis of research on national HIV pre-exposure prophylaxis programmes among gay, bisexual, and other men who have sex with men.HRB open research · 2024Article
- Estimating the epidemiological impact of reaching the objectives of the Florida integrated HIV prevention and care plan in Miami-Dade County.Lancet regional health. Americas · 2023Article
- Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis.JAMA network open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The U.S. has the tools to end the HIV epidemic, but progress has stagnated. A major gap in U.S. efforts to address HIV is the under-utilization of medications that can virtually eliminate acquisition of the virus, known as pre-exposure prophylaxis (PrEP). This document proposes a financing and delivery system to unlock broad access to PrEP for those most vulnerable to HIV acquisition and bring an end to the HIV epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.